RAS/CBL突变预测骨髓纤维化患者对JAK抑制剂耐药并关联不良预后特征
该研究纳入464例连续骨髓纤维化(MF)患者,检出59例(12.7%)携带RAS/CBL突变,包括NRAS、KRAS和CBL突变。RAS/CBL突变与高危临床及分子特征相关,总生存期较差,且5年白血病转化累积发生率显著更高。在61例接受JAK抑制剂治疗的患者中,RAS/CBL突变组6个月症状和脾脏缓解率显著更低,多因素分析显示突变与缓解概率呈显著负相关。
要点
- RAS/CBL突变见于12.7%的骨髓纤维化患者,与高危特征和不良生存相关。
- RAS/CBL突变患者5年白血病转化累积发生率显著更高。
- RAS/CBL突变预测JAK抑制剂治疗6个月症状和脾脏缓解率降低。
核心结论
- RAS/CBL突变与骨髓纤维化患者不良表型特征和生存结局相关,并可能预测对JAK抑制剂反应降低。
研究设计与样本
- 回顾性研究纳入464例连续骨髓纤维化患者,分析RAS/CBL突变的表型、预后和治疗意义。
- 61例患者接受JAK抑制剂治疗,中位观察时间30个月。
主要发现
- 59例(12.7%)患者携带RAS/CBL突变:NRAS突变25例(5.4%),KRAS突变13例(2.8%),CBL突变26例(5.6%)。
- RAS/CBL突变患者更常见高危临床和分子特征,总生存期较无突变患者差,在多因素模型(含MIPSS70风险因素和细胞遗传学)中保持显著性。
- RAS/CBL突变组5年白血病转化累积发生率显著更高。
- 接受JAK抑制剂治疗的患者中,RAS/CBL突变组6个月症状和脾脏缓解率显著更低,Logistic回归显示突变与缓解概率显著负相关,多因素分析中保持显著。
关键数值与推荐
- RAS/CBL突变率12.7%(59/464),NRAS 5.4%(25/464),KRAS 2.8%(13/464),CBL 5.6%(26/464)。
- 将RAS/CBL突变纳入分子注释预后模型未改善预测能力。
- JAK抑制剂治疗患者中位观察30个月,RAS/CBL突变组6个月症状和脾脏缓解率显著更低。
临床怎么用
- 对骨髓纤维化患者进行RAS/CBL突变检测有助于识别高危、预后不良及可能对JAK抑制剂反应不佳的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The dysregulation of the JAK/STAT pathway drives the pathogenesis of myelofibrosis (MF). Recently, several JAK inhibitors (JAKis) have been developed for treating MF. Select mutations (MTs) have been associated with impaired outcomes and are currently incorporated in molecularly annotated prognostic models. Mutations of RAS/MAPK pathway genes are frequently reported in cancer and at low frequencies in MF. In this study, we investigated the phenotypic, prognostic, and therapeutic implications of NRASMTs, KRASMTs, and CBLMTs (RAS/CBLMTs) in 464 consecutive MF patients. A total of 59 (12.7%) patients had RAS/CBLMTs: NRASMTs, n = 25 (5.4%); KRASMTs, n = 13 (2.8%); and CBLMTs, n = 26 (5.6%). Patients with RAS/CBLMTs were more likely to present with high-risk clinical and molecular features. RAS/CBLMTs were associated with inferior overall survival compared with patients without MTs and retained significance in a multivariate model, including the Mutation-Enhanced International Prognostic Score System (MIPSS70) risk factors and cytogenetics; however, inclusion of RAS/CBLMTs in molecularly annotated prognostic models did not improve the predictive power of the latter. The 5-year cumulative incidence of leukemic transformation was notably higher in the RAS/CBLMT cohort. Among 61 patients treated with JAKis and observed for a median time of 30 months, the rate of symptoms and spleen response at 6 months was significantly lower in the RAS/CBLMT cohort. Logistic regression analysis disclosed a significant inverse correlation between RAS/CBLMTs and the probability of achieving a symptom or spleen response that was retained in multivariate analysis. In summary, our study showed that RAS/CBLMTs are associated with adverse phenotypic features and survival outcomes and, more important, may predict reduced response to JAKis.
引用
- Coltro G, Rotunno G, Mannelli L, et al. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Adv. 2020. PMID: 32777067. doi:10.1182/bloodadvances.2020002175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。